| Summary: | T-type calcium channel (Ca<sub>V</sub>3.x) blockers are receiving increasing attention as potential therapeutics for the treatment of pathophysiological disorders and diseases, including absence epilepsy, Parkinson’s disease (PD), hypertension, cardiovascular diseases, cancers, and pain. However, few clinically approved Ca<sub>V</sub>3.x blockers are available, and selective pharmacological tools are needed to further unravel the roles of individual Ca<sub>V</sub>3.x subtypes. In this work, through an efficient synthetic route to the marine fungal product pseudellone C, we obtained bisindole alkaloid analogs of pseudellone C with a modified tryptophan moiety and identified two Ca<sub>V</sub>3.2 (<b>2</b>, IC<sub>50</sub> = 18.24 µM; <b>3</b>, IC<sub>50</sub> = 6.59 µM) and Ca<sub>V</sub>3.3 (<b>2</b>, IC<sub>50</sub> = 7.71 µM; <b>3</b>, IC<sub>50</sub> = 3.81 µM) selective blockers using a FLIPR cell-based assay measuring Ca<sub>V</sub>3.x window currents. Further characterization by whole-cell patch-clamp revealed a preferential block of Ca<sub>V</sub>3.1 activated current (<b>2</b>, IC<sub>50</sub> = 5.60 µM; <b>3</b>, IC<sub>50</sub> = 9.91 µM), suggesting their state-dependent block is subtype specific.
|
|---|